Premium
Prevention of hypoglycaemia in a patient with type Ib glycogen storage disease by an amylase (α‐glucosidase) inhibitor
Author(s) -
Ihara K,
Kuromaru R,
Ryu A,
Fukushige J,
Hara T
Publication year - 1998
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.1998.tb01511.x
Subject(s) - medicine , hypoglycemia , amylase , glycogen , incidence (geometry) , glycogen storage disease , glycogen storage disease type i , gastroenterology , endocrinology , insulin , biochemistry , enzyme , biology , physics , optics
Patients with type Ib glycogen storage disease (GSD Ib) are susceptible to hypoglycaemic episodes. To determine whether an amylase (α‐glucosidase) inhibitor, voglibose, can be useful in the control of hypoglycaemia, we tried it in a 14‐y‐old male with GSD Ib. Oral administration of voglibose prolonged the duration of normoglycaemia and reduced the incidence of hypoglycaemia attacks. These findings indicate that voglibose may be useful for preventing hypoglycaemia in GSD Ib patients.